Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 19/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18160959 | 0.90 | VCP (0.61) | VCPPRKDC | |
| SCHEMBL16796043 | 0.88 | VCP (0.61) | VCPKDM4EALDH1A1HPGDCRHBP | |
| SCHEMBL16796296 | 0.85 | VCP (0.61) | VCPKDM4EALDH1A1 | |
| SCHEMBL16796171 | 0.84 | VCP (0.61) | VCPKDM4EALDH1A1HPGD | |
| SCHEMBL16796064 | 0.83 | VCP (0.58) | VCP | |
| SCHEMBL16796269 | 0.83 | VCP (0.67) | VCPPRKDC | |
| SCHEMBL16796204 | 0.83 | VCP (0.58) | VCPPRKDC | |
| SCHEMBL16796209 | 0.83 | VCP (0.60) | VCPPRKDC | |
| SCHEMBL18163784 | 0.83 | VCP (0.52) | VCPPRKDC | |
| SCHEMBL16796078 | 0.83 | VCP (0.57) | VCPPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2015089218-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | WUSTROW DAVID (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | PSMG3, PSMD2, PSME1 | VCP 67/4885KDM4E 2933/4885ALDH1A1 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.